Nevertheless, we were still able to validate in snRNAseq the bulk RNAseq expression changes in the corresponding nuclei type that led to the discovery of DDR2, KANK2, and STOM as potential therapeutic targets for PSP. The gene discussed is STOM; the disease is supranuclear palsy, progressive, 1.